AVBP (STOCKS)
ArriVent BioPharma, Inc. Common Stock
$31.740000
+0.380000 (+1.21%)
Prev close: $31.360000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- CEO
- Zheng Bin Yao
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,478.29M
- Employees
- 52
- P/E (TTM)
- -8.99
- P/B (TTM)
- 4.44
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
7
Strong Buy
11
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.96 | $-0.91 | -0.0474 | -5.19% |
|
Dec 2025 (Q4)
|
$-0.78 | $-0.86 | +0.0843 | +9.75% |
|
Sep 2025 (Q3)
|
$-0.83 | $-0.81 | -0.0249 | -3.09% |
|
Jun 2025 (Q2)
|
$-0.90 | $-0.72 | -0.1822 | -25.38% |
Financial Statements
| Revenues | $0.00 |
| Operating Expenses | $156.87M |
| Research and Development | $129.68M |
| Other Operating Expenses | $27.19M |
| Operating Income/Loss | -$156.87M |
| Income/Loss From Continuing Operations After Tax | -$145.24M |
| Income/Loss From Continuing Operations Before Tax | -$145.24M |
| Net Income/Loss | -$145.24M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$145.24M |
| Net Income/Loss Available To Common Stockholders, Basic | -$145.24M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.47 |
| Diluted Earnings Per Share | -$3.47 |
| Basic Average Shares | 123,480,299 |
| Diluted Average Shares | 123,480,299 |
| Assets | $349.30M |
| Current Assets | $348.70M |
| Noncurrent Assets | $595.00K |
| Liabilities | $25.32M |
| Current Liabilities | $25.00M |
| Accounts Payable | $8.73M |
| Wages | $1.93M |
| Other Current Liabilities | $14.34M |
| Noncurrent Liabilities | $320.00K |
| Equity | $323.98M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $323.98M |
| Liabilities And Equity | $349.30M |
| Net Cash Flow From Operating Activities | -$134.47M |
| Net Cash Flow From Operating Activities, Continuing | -$134.47M |
| Net Cash Flow From Investing Activities | -$104.47M |
| Net Cash Flow From Investing Activities, Continuing | -$104.47M |
| Net Cash Flow From Financing Activities | $251.18M |
| Net Cash Flow From Financing Activities, Continuing | $251.18M |
| Net Cash Flow | $12.24M |
| Net Cash Flow, Continuing | $12.24M |
| Comprehensive Income/Loss | -$145.49M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$145.49M |
| Other Comprehensive Income/Loss | -$253.00K |